Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Conference News AHA 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

Shelley Wood

November 06, 2022

News Daily News

Still No Edge for Bivalirudin in VALIDATE-SWEDEHEART’s STEMI Patients

Shelley Wood

December 22, 2021

News Conference News TCT 2020

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

Shelley Wood

October 14, 2020

News Conference News CRT 2018

Radial Access PCI Reduces Risk of Mortality and Bleeding in VALIDATE-SWEDEHEART

Michael O'Riordan

March 06, 2018

Presentation TCT 2017

VALIDATE-SWEDEHEART NSTEMI: A Randomized Trial of Bivalirudin vs Heparin Monotherapy in Patients With NSTEMI

Presenter: Thomas F. Luscher, David Erlinge

October 31, 2017

Presentation TCT 2017

VALIDATE-SWEDEHEART STEMI: A Randomized Trial of Bivalirudin vs Heparin Monotherapy in Patients With STEMI

Presenter: Y. S. Chandrashekhar, David J. Moliterno, Stefan K. James

October 31, 2017

News Opinion Editor's Corner ESC 2017

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

Shelley Wood

September 08, 2017

News Conference News ESC 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

Shelley Wood

August 27, 2017

Presentation ESC 2017

Bivalirudin vs Heparin Monotherapy in Myocardial Infarction:The VALIDATE-SWEDEHEART Trial

Presenter: David Erlinge

August 27, 2017

Presentation TCT 2015

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

Presenter: John A. Bittl, Robert A. Harrington, David Erlinge

October 12, 2015

News Daily News

SCAAR: Stent Thrombosis Risk After Primary PCI No Higher With Bivalirudin Than Other Antithrombotics

Todd Neale

February 19, 2015

News Conference News EuroPCR 2013

Registry Questions Superiority of Bivalirudin Over Heparin Alone in NSTE-ACS

Yael L. Maxwell

May 23, 2013

Advertisement

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

Still No Edge for Bivalirudin in VALIDATE-SWEDEHEART’s STEMI Patients

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

Radial Access PCI Reduces Risk of Mortality and Bleeding in VALIDATE-SWEDEHEART

VALIDATE-SWEDEHEART NSTEMI: A Randomized Trial of Bivalirudin vs Heparin Monotherapy in Patients With NSTEMI

VALIDATE-SWEDEHEART STEMI: A Randomized Trial of Bivalirudin vs Heparin Monotherapy in Patients With STEMI

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

Bivalirudin vs Heparin Monotherapy in Myocardial Infarction:The VALIDATE-SWEDEHEART Trial

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

SCAAR: Stent Thrombosis Risk After Primary PCI No Higher With Bivalirudin Than Other Antithrombotics

Registry Questions Superiority of Bivalirudin Over Heparin Alone in NSTE-ACS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content